Healx Doses First Patient in Phase 1/2 Trial of HLX-4310, Targeting Metastatic Recurrence in Osteosarcoma
核心洞察
Healx (搜索) has dosed the first patient in a Phase 1/2 trial evaluating HLX-4310 (搜索), an oral combination of a class I selective HDAC (搜索) inhibitor and an mTOR (搜索) inhibitor, in adolescents and adults with relapsed, refractory sarcoma.
The trial focuses on preventing metastatic recurrence rather than shrinking visible tumors, targeting the biology of micro-metastatic dormancy that conventional chemotherapy fails to address.
Metastatic osteosarcoma (搜索) carries a five-year survival rate of less than 30%, a figure that has remained largely unchanged for four decades despite intensified chemotherapy regimens.
Healx (搜索), an AI-powered clinical-stage biotech company based in Cambridge, UK, announced on July 22, 2026 that the first patient has been dosed in its Phase 1/2 dose-escalation and dose-confirmation clinical trial evaluating HLX-4310 (搜索). The investigational oral combination—comprising a class I selective histone deacetylase (HDAC (搜索)) inhibitor and an mTOR (搜索) inhibitor—is being studied in adolescents and adults with relapsed, refractory sarcoma, with a particular focus on osteosarcoma (搜索).
The trial represents a notable mechanistic departure from conventional oncology development. Rather than aiming to shrink visible tumors, HLX-4310 (搜索) is designed to prevent metastatic recurrence by targeting the biological programs that enable micro-metastatic tumors to survive at distant sites and later re-emerge as lethal disease. This approach addresses a fundamental limitation of cytotoxic chemotherapy, which effectively targets actively proliferating cells but does far less against dormant disseminated tumor cells that can reactivate months or years after apparent remission.
The Unmet Need in Osteosarcoma (搜索)
Osteosarcoma (搜索) is the most common type of bone cancer in children and adolescents. For patients who develop metastatic disease, outcomes remain dire: the five-year survival rate stands at less than 30%, a statistic that has barely shifted in four decades despite increasingly intensive chemotherapy regimens. Approved treatment options for relapsed and refractory osteosarcoma remain extremely limited, with no therapy specifically cleared for that indication since the 1970s.
"Metastatic osteosarcoma (搜索) is so difficult to treat because patients can undergo intensive therapy, reach remission, and still relapse within months or within several years," said David Warshawsky, Ph.D., Global Head of Metastatic Prevention at Healx (搜索). "We believe that HLX-4310 (搜索) provides a novel and differentiated approach focused on the unique biology hypothesized to drive cancer recurrence, and we are delighted to see it advance into trials."
Mechanism and Scientific Rationale
HLX-4310 (搜索) combines two agents with complementary activity profiles. The class I selective HDAC (搜索) inhibitor is intended to modulate epigenetic programs governing tumor-cell survival and tumor-immune crosstalk, while the mTOR (搜索) inhibitor targets a central pathway involved in cell growth, metabolism, and stress responses. The combination logic rests on the premise that micro-metastatic dormancy biology is genuinely distinct from the biology of active tumor growth, and therefore requires a distinct therapeutic strategy.
The relapsed/refractory setting provides a patient population in which the recurrence biology Healx (搜索) is targeting is already in full expression. Notably, a prior mTOR (搜索)-inhibitor new drug application for sarcoma received a Complete Response Letter from the FDA in 2012, underscoring the historical difficulty of converting single-agent mTOR activity in this tumor type into regulatory approval.
Trial Design and Partnership
The Phase 1/2 open-label, cohort sequential dose-escalation and dose-confirmation trial is being advanced in collaboration with the National Pediatric Cancer Foundation (搜索)'s (NPCF) flagship research program, the Sunshine Project. This consortium coordinates more than thirty pediatric cancer centers across the United States—infrastructure that is critical for enrollment given that osteosarcoma (搜索) is rare and the relapsed/refractory subgroup is rarer still.
"I'm excited to see this study begin dosing patients and to evaluate a strategy that is explicitly focused on preventing metastatic recurrence," said Amy Armstrong, M.D., Principal Investigator for the Phase 1/2 HLX-4310 (搜索) trial. "This trial will evaluate the safety and tolerability of HLX-4310 and assess efficacy, including its potential to reduce cancer recurrence risk."
David Frazer, President of the National Pediatric Cancer Foundation (搜索), added: "Our consortium brings together leading pediatric cancer centers to accelerate promising science into clinical studies. This trial reflects the shared commitment of the Sunshine Project and Healx (搜索) to drive progress for children and young adults facing high-risk cancers like osteosarcoma (搜索)."
Broader Implications
Healx (搜索), which has raised more than $100 million to date, is positioning HLX-4310 (搜索) as the first clinical proof point for a broader metastatic-prevention franchise. The company's pipeline also includes HLX-1502 in neurofibromatosis Type 1. If the biology underlying the dormancy-targeting hypothesis holds, the company argues the approach could extend to other cancer types where metastatic recurrence shares biological mechanisms, including breast cancer, renal cell carcinoma, and melanoma.
The most consequential endpoint to track as the trial matures will be the recurrence-free interval in the Phase 2 cohort. A meaningful extension of time between remission and relapse would validate the dormancy-targeting hypothesis and provide a credible scientific foundation for broader oncology indications. Conversely, a short recurrence-free benefit—or none at all—would challenge the entire platform rationale, not just this single compound.